Skip to content
MarketScale
‹ Back to IndustriesSciences

Can Intermittent Fasting Help You Lose Weight And Provide Other Health Benefits?

While it has been widely promoted as a weight loss strategy, research suggests that intermittent fasting may have broader benefits for overall health and well-being. A study published in the New England Journal of Medicine found that Intermittent Fasting can help lower blood pressure, improve insulin sensitivity, and reduce the risk of chronic diseases such…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Healthcare · DietFastingHealthHealth Benefits
Share

Key takeaways

01

While it has been widely promoted as a weight loss strategy, research suggests that intermittent fasting may have broader benefits for overall health and well-being.

02

A study published in the New England Journal of Medicine found that Intermittent Fasting can help lower blood pressure, improve insulin sensitivity, and reduce the risk of chronic diseases such…

While it has been widely promoted as a weight loss strategy, research suggests that intermittent fasting may have broader benefits for overall health and well-being. A study published in the New England Journal of Medicine found that Intermittent Fasting can help lower blood pressure, improve insulin sensitivity, and reduce the risk of chronic diseases such as diabetes and heart disease.

Another study in the journal Cell Metabolism found that Intermittent Fasting can increase the production of a protein called brain-derived neurotrophic factor (BDNF), which is essential for the growth and maintenance of neurons in the brain.

Despite these promising findings, new research found that intermittent fasting may not be as beneficial for weight loss as previously thought while another study found that that it does not bring the same health benefits as other weight loss programs.

These new findings leave lots of questions unanswered. Does intermittent fasting help with weight loss and provide other health benefits or is it just another fad diet targeted to those who are looking to lose weight? Kimberly Gomer, director of nutrition at Body Beautiful Miami, is a leading nutritional expert in weight loss and medical nutrition for over 2 decades. She brings her years of experience to the discussion and offers her in-depth analysis of this dietary strategy.

Kim’s Thoughts:

I love this article on intermittent fasting because it brings to light an unknown idea for a lot of people. I do believe from the science, looking at the science, that there is benefit to time-restricted eating. So, you’re fasting for a certain amount of time and then you’re eating. The idea that immune autophagy maintaining muscle mass is a possibility with fasting.

But the exciting part for me as a nutritionist is the stability of blood sugar. Because high insulin levels, high blood sugars are a huge problem in the United States—we are looking at one in three people with prediabetes. We are looking at one in 10 people with diabetes, and we are looking at one in five people who don’t even know they have it.

So, this idea that we can lower insulin levels and we can stabilize blood sugar and do it through an intermittent fasting lifestyle, is amazing. And part of the science behind it is that when you are not eating, be it sleeping or just not eating, your insulin is very low. It’s the lowest when you’re not eating so allowing for a time that you are not eating in your day to be extended and eating only in a certain window, there are a lot of health benefits.

The problem that I see with some of these articles and understanding how they would apply to you as an individual is the fasting times are all over the place. Are you fasting for 18 hours a day? Are you fasting for 16 hours a day? Are you fasting for 12 hours a day?

Is your eating window very short? One to three hours or long eight hours. So, this idea of what is the best fasting and eating window is still not clear in some of the research, and more important in my mind, yes, intermittent fasting is a great tool. I use it in my private practice as a dietician with a lot of success.

But one thing that has to come with it is what are you eating? We live in a world of obesogenic food, highly processed, unhealthy food. So, some of my clients actually think, some people think well I can fast for 20 hours and for four hours I can go and eat fast food and eat junk, and I’m going to be healthy and thin. Not true.

So, I love intermittent fasting, I think we need more and more research about it. I think people need to be clear about what will work for them, how the tool can work for them as an individual, and more importantly, be clear about what they’re actually eating during their window. Again, I’m going to say I think that intermittent fasting is an awesome tool.

I’m so happy to see research being published. More research needs to be done and I think it can be very useful for a lot of people. Thank you.

About the author

H
Healthcare

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512